Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clear view on diquafosol

Inspire Pharmaceuticals Inc. is not overly concerned about the failure of its 2% diquafosol tetrasodium drops in treating dry eye in a controlled adverse environment (CAE) chamber. The company says that the success of INS365 in reducing

Read the full 373 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers